Reproductive Health — MCQs
On this page
A 51-year-old woman with a BMI of 29 kg/m² presents requesting HRT for moderate vasomotor symptoms. She smokes 10 cigarettes per day and has blood pressure of 145/92 mmHg measured on two occasions. She has no personal or family history of venous thromboembolism or breast cancer. Her mother had a myocardial infarction at age 68. What is the most appropriate initial management?
A 40-year-old nulliparous woman has had the levonorgestrel intrauterine system in situ for 3 years for contraception and management of heavy menstrual bleeding. She has been amenorrhoeic for the past 18 months and is very satisfied. She asks how long the device can remain in place. What is the correct licensed duration for this device when used for contraception?
A 49-year-old woman presents with troublesome vasomotor symptoms affecting her sleep and quality of life. She had a deep vein thrombosis 8 years ago during pregnancy, which was treated with 6 months of anticoagulation. Thrombophilia screening at the time was negative. She has no other medical conditions. What is the most appropriate management of her menopausal symptoms?
A 33-year-old woman with well-controlled HIV infection on antiretroviral therapy (efavirenz, tenofovir, and emtricitabine) attends for contraceptive counselling. Her CD4 count is 650 cells/mm³ and viral load is undetectable. She is in a stable relationship and requests effective contraception. Which contraceptive method is most appropriate?
A 54-year-old woman who has been taking continuous combined HRT for 18 months presents with a single episode of vaginal bleeding. She had her last natural period 3 years ago. She is otherwise well and examination is normal. Transvaginal ultrasound shows an endometrial thickness of 6 mm with no focal lesions. What is the most appropriate management?
A 28-year-old woman with body mass index of 36 kg/m² requests long-acting reversible contraception. She has no other medical conditions and is a non-smoker. She is particularly concerned about weight gain with contraception. Which of the following statements regarding contraceptive options and weight is most accurate?
A 50-year-old woman commenced on sequential combined HRT 4 months ago presents with withdrawal bleeding lasting 10 days, which is significantly heavier than her previous natural periods. Her cervical screening is up-to-date and normal. Abdominal and bimanual examination are unremarkable. What is the most appropriate initial investigation?
A 37-year-old woman with a BMI of 32 kg/m² presents requesting contraception. She has a history of migraine without aura occurring approximately twice monthly, well-controlled hypertension on ramipril 5 mg daily (blood pressure today 128/82 mmHg), and type 2 diabetes diagnosed 2 years ago managed with metformin (HbA1c 48 mmol/mol with no microvascular complications). She is a non-smoker. According to UK Medical Eligibility Criteria, which contraceptive method is classified as UKMEC 1 (no restriction) for this patient?
What is the minimum duration that women over the age of 50 years should continue using contraception after their last menstrual period to prevent pregnancy?
A 52-year-old woman who underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy 8 weeks ago for endometriosis presents with severe vasomotor symptoms affecting her quality of life and work performance. She has no personal or family history of venous thromboembolism or breast cancer. What is the most appropriate initial hormone replacement therapy regimen?
Reproductive Health UK Medical PG Practice Questions and MCQs
Question 111: A 51-year-old woman with a BMI of 29 kg/m² presents requesting HRT for moderate vasomotor symptoms. She smokes 10 cigarettes per day and has blood pressure of 145/92 mmHg measured on two occasions. She has no personal or family history of venous thromboembolism or breast cancer. Her mother had a myocardial infarction at age 68. What is the most appropriate initial management?
- A. Prescribe transdermal estradiol with micronised progesterone as the cardiovascular risk is acceptable
- B. Commence standard combined oral HRT as she is within 10 years of menopause and benefits outweigh risks
- C. Offer lifestyle modification advice and smoking cessation support, then reassess her suitability for HRT (Correct Answer)
- D. Prescribe tibolone as it has a more favourable cardiovascular profile than standard HRT
- E. Advise that HRT is contraindicated due to her hypertension and smoking status and offer SSRI therapy
Explanation: ***Offer lifestyle modification advice and smoking cessation support, then reassess her suitability for HRT*** - This patient has significant **modifiable cardiovascular risk factors**, including **uncontrolled hypertension (145/92 mmHg)** and active **smoking**, which must be addressed before initiating hormonal therapy. - **NICE guidelines** emphasize that blood pressure should be controlled and lifestyle factors optimized to minimize the risk of **stroke** and **venous thromboembolism** associated with HRT. *Prescribe transdermal estradiol with micronised progesterone as the cardiovascular risk is acceptable* - Although **transdermal estradiol** and **micronised progesterone** have a better safety profile regarding VTE than oral options, they should not be started while blood pressure remains **uncontrolled**. - Initiating HRT without addressing the **smoking status** ignores the synergistically increased risk of **myocardial infarction** and **stroke** in this age group. *Commence standard combined oral HRT as she is within 10 years of menopause and benefits outweigh risks* - **Oral HRT** is specifically associated with a higher risk of **venous thromboembolism (VTE)** and is generally avoided in patients with a high **BMI** or those who smoke. - While she is in the "window of opportunity" (within 10 years of menopause), her **uncontrolled hypertension** and smoking make oral estrogen an inappropriate first-line choice. *Prescribe tibolone as it has a more favourable cardiovascular profile than standard HRT* - **Tibolone** is actually associated with an increased risk of **stroke** in women over 60 or those with established cardiovascular risk factors, and does not offer a superior cardiovascular safety profile for this patient. - Like other HRT forms, it should only be considered once **blood pressure** is stabilized and other **cardiovascular risks** are managed. *Advise that HRT is contraindicated due to her hypertension and smoking status and offer SSRI therapy* - Hypertension and smoking are **relative**, not absolute, contraindications for HRT; HRT can often be prescribed safely once blood pressure is **controlled below 140/90 mmHg** and smoking cessation achieved. - **SSRI therapy** is an alternative for vasomotor symptoms but is usually reserved for those with **absolute contraindications** or those who do not wish to take hormones, after lifestyle modifications have been attempted.
Question 112: A 40-year-old nulliparous woman has had the levonorgestrel intrauterine system in situ for 3 years for contraception and management of heavy menstrual bleeding. She has been amenorrhoeic for the past 18 months and is very satisfied. She asks how long the device can remain in place. What is the correct licensed duration for this device when used for contraception?
- A. 3 years
- B. 5 years (Correct Answer)
- C. 6 years
- D. 8 years
- E. 10 years
Explanation: ***5 years*** - The **Mirena** (52 mg levonorgestrel-releasing IUS) is currently **licensed for 5 years** when used for **contraception** and management of **heavy menstrual bleeding**. - While recent FSRH guidance suggests some 52 mg systems can be used for up to 6 years off-label, the standard **licensed duration** remains 5 years for a 40-year-old patient. *3 years* - This is the licensed duration for the **Jaydess** (13.5 mg) IUS and the **Nexplanon** contraceptive implant, but not the 52 mg LNG-IUS. - Using a 52 mg LNG-IUS for only 3 years would result in premature replacement, as its hormone reservoir is designed for **longer efficacy**. *6 years* - Although some clinical evidence and updated UK guidelines (FSRH) support **off-license** contraceptive use of certain 52 mg IUS devices for 6 years, this is not currently the standard **product license**. - This duration does not apply to the **endometrial protection** component of HRT, which is typically licensed for 4 to 5 years. *8 years* - There is currently no levonorgestrel intrauterine system with a **primary license** for 8 years of use in the UK or major international markets. - Recent studies are investigating **extended use**, but any use beyond 5 or 6 years is currently considered **experimental/off-license**. *10 years* - This duration is typical for **non-hormonal copper IUDs** (such as the **Copper T380A**), which provide long-term protection without hormone release. - An LNG-IUS inserted **after age 45** may sometimes be used until menopause, but it is not licensed for a flat 10-year term for a 40-year-old.
Question 113: A 49-year-old woman presents with troublesome vasomotor symptoms affecting her sleep and quality of life. She had a deep vein thrombosis 8 years ago during pregnancy, which was treated with 6 months of anticoagulation. Thrombophilia screening at the time was negative. She has no other medical conditions. What is the most appropriate management of her menopausal symptoms?
- A. Commence standard-dose transdermal estradiol HRT as more than 5 years have passed since her VTE
- B. Offer selective serotonin reuptake inhibitor therapy as HRT is absolutely contraindicated (Correct Answer)
- C. Commence low-dose oral estradiol HRT with close monitoring
- D. Prescribe tibolone as it has lower VTE risk than standard HRT
- E. Refer to haematology for assessment before considering any form of HRT
Explanation: ***Offer selective serotonin reuptake inhibitor therapy as HRT is absolutely contraindicated*** - A prior history of **venous thromboembolism (VTE)**, such as DVT, is considered an **absolute contraindication** to any form of Hormone Replacement Therapy (HRT) due to the increased risk of recurrence. - **Selective serotonin reuptake inhibitors (SSRIs)** or serotonin-norepinephrine reuptake inhibitors (SNRIs) are effective and safe **non-hormonal alternatives** for managing severe vasomotor symptoms. *Commence standard-dose transdermal estradiol HRT as more than 5 years have passed since her VTE* - While **transdermal HRT** carries a lower VTE risk than oral HRT, a history of DVT still represents a contraindication, as the risk is not entirely eliminated. - The passage of **5 years** since the DVT does not negate the fundamental increased risk associated with exogenous hormonal therapy in a patient with a thrombotic history. *Commence low-dose oral estradiol HRT with close monitoring* - **Oral estradiol** is associated with a significantly increased risk of VTE (2-3 fold) due to its effects on hepatic coagulation factors. - **Low-dose** oral HRT or **close monitoring** does not sufficiently mitigate this unacceptable risk in a patient with a confirmed history of DVT. *Prescribe tibolone as it has lower VTE risk than standard HRT* - **Tibolone** is a synthetic steroid with estrogenic properties that, despite some debate on its VTE risk compared to conventional HRT, is generally **contraindicated** in individuals with a history of thromboembolic disease. - It is not recommended as a safe alternative for patients with a known risk of **thrombosis**. *Refer to haematology for assessment before considering any form of HRT* - A **haematology referral** is typically not required to determine HRT suitability in this scenario, as the history of DVT is a well-established and clear **absolute contraindication**. - Even with a negative **thrombophilia screening**, the clinical history of the previous VTE remains the overriding factor precluding hormonal treatment.
Question 114: A 33-year-old woman with well-controlled HIV infection on antiretroviral therapy (efavirenz, tenofovir, and emtricitabine) attends for contraceptive counselling. Her CD4 count is 650 cells/mm³ and viral load is undetectable. She is in a stable relationship and requests effective contraception. Which contraceptive method is most appropriate?
- A. Combined oral contraceptive pill as efavirenz does not affect its efficacy
- B. Depot medroxyprogesterone acetate 150 mg intramuscularly every 12 weeks
- C. Levonorgestrel intrauterine system 52 mg (Correct Answer)
- D. Progesterone-only pill containing levonorgestrel 30 mcg
- E. Etonogestrel implant with additional barrier contraception recommended
Explanation: ***Levonorgestrel intrauterine system 52 mg***- The **Levonorgestrel intrauterine system (LNG-IUS)** is highly effective and acts primarily locally, making it **unaffected by enzyme-inducing drugs** like efavirenz.- It is classified as **UKMEC 1** for patients with well-controlled HIV (CD4 >200 cells/mm³), providing long-acting reversible contraception without significant drug-drug interactions.*Combined oral contraceptive pill as efavirenz does not affect its efficacy*- **Efavirenz** is a potent **cytochrome P450 enzyme inducer** that significantly reduces the serum levels of ethinylestradiol and progestogens.- Due to the high risk of **contraceptive failure**, the combined pill is classified as **UKMEC 3** when used with efavirenz.*Depot medroxyprogesterone acetate 150 mg intramuscularly every 12 weeks*- While **DMPA** is not significantly affected by enzyme-inducing drugs and can be used, the **LNG-IUS** offers a more continuous and lower systemic hormonal exposure.- It is generally considered **UKMEC 1** or **UKMEC 2** for women with HIV, though long-term use can be associated with **bone mineral density loss**.*Progesterone-only pill containing levonorgestrel 30 mcg*- Standard-dose **progesterone-only pills (POP)** are highly susceptible to **hepatic enzyme induction**, leading to rapidly declining hormone levels and reduced efficacy.- This method is categorized as **UKMEC 3** because its reliability is compromised in patients taking **efavirenz**.*Etonogestrel implant with additional barrier contraception recommended*- The **etonogestrel implant** efficacy is significantly reduced by **enzyme inducers** like efavirenz, potentially leading to breakthrough ovulation and pregnancy.- It is managed as **UKMEC 2/3**; while it can be used with caution, it is less ideal than the **LNG-IUS** which requires no additional precautions due to its localized action.
Question 115: A 54-year-old woman who has been taking continuous combined HRT for 18 months presents with a single episode of vaginal bleeding. She had her last natural period 3 years ago. She is otherwise well and examination is normal. Transvaginal ultrasound shows an endometrial thickness of 6 mm with no focal lesions. What is the most appropriate management?
- A. Reassure and review if bleeding recurs
- B. Perform endometrial biopsy (Correct Answer)
- C. Switch to sequential combined HRT
- D. Increase the progestogen component of her HRT
- E. Stop HRT and repeat ultrasound in 3 months
Explanation: ***Perform endometrial biopsy*** - Any **vaginal bleeding** that occurs after the first **6 months** of continuous combined **hormone replacement therapy (HRT)** in a postmenopausal woman must be investigated to rule out **endometrial malignancy**. - The **endometrial thickness of 6 mm** in this context exceeds the typical threshold (usually **4-5 mm**), necessitating an endometrial sample via **Pipelle biopsy** or hysteroscopy for histological assessment. *Reassure and review if bleeding recurs* - Reassurance is inappropriate because **unscheduled bleeding** after the 6-month adjustment period on HRT is a **red flag** for **endometrial hyperplasia** or cancer. - Waiting for recurrence could dangerously delay the diagnosis of a **potentially curable malignancy** in a postmenopausal woman. *Switch to sequential combined HRT* - **Sequential HRT** is intended for **perimenopausal women** to induce monthly bleeds, whereas this patient is **postmenopausal** and has been on continuous combined HRT. - Switching regimens does not address the urgent clinical need to investigate the **pathological cause** of her current bleeding episode. *Increase the progestogen component of her HRT* - While progestogen protects the endometrium, increasing the dose before obtaining a **histological diagnosis** is premature and potentially unsafe. - It is critical to first exclude **atypical hyperplasia** or **endometrial carcinoma** before making adjustments to the HRT composition. *Stop HRT and repeat ultrasound in 3 months* - Stopping HRT may temporarily halt the bleeding but does not provide a definitive diagnosis for the **thickened endometrium** observed. - **Delayed investigation** by three months is contrary to urgent **referral guidelines** for suspected postmenopausal gynecological cancers.
Question 116: A 28-year-old woman with body mass index of 36 kg/m² requests long-acting reversible contraception. She has no other medical conditions and is a non-smoker. She is particularly concerned about weight gain with contraception. Which of the following statements regarding contraceptive options and weight is most accurate?
- A. The levonorgestrel intrauterine system is associated with significant weight gain in most users
- B. Depot medroxyprogesterone acetate is the most suitable LARC option as it does not cause weight gain
- C. The etonogestrel implant has the strongest evidence for causing clinically significant weight gain
- D. The copper intrauterine device has no effect on weight and provides highly effective contraception (Correct Answer)
- E. Combined hormonal contraceptives should be avoided solely due to obesity-related weight gain concerns
Explanation: ***The copper intrauterine device has no effect on weight and provides highly effective contraception*** - As a **non-hormonal** method, the copper IUD has no metabolic effect on body weight, making it an ideal choice for a patient with a **high BMI** concerned about weight gain. - It offers over **99% efficacy** and is classified as **UKMEC 1** for patients with obesity, indicating no restriction for use. *The levonorgestrel intrauterine system is associated with significant weight gain in most users* - The **LNG-IUS** acts primarily through local effects on the endometrium with **minimal systemic absorption**, and clinical trials do not show a significant link to weight gain in most users. - Any fluctuations in weight observed are generally comparable to those seen in aging populations not using hormonal contraception. *Depot medroxyprogesterone acetate is the most suitable LARC option as it does not cause weight gain* - **DMPA** is the only contraceptive method consistently linked with **clinically significant weight gain**, particularly in women who have a high BMI at the start of use. - It is classified as **UKMEC 2** (or UKMEC 3 if other factors exist) for obesity, and some users gain an average of **2-3 kg** over a year. *The etonogestrel implant has the strongest evidence for causing clinically significant weight gain* - While some studies show minimal fluctuations (average **<1 kg**), evidence for the implant causing major weight gain remains **inconsistent and weak** compared to DMPA. - Many women perceive weight gain with the implant, but large prospective studies fail to confirm a definitive causal link to significant adipose increase. *Combined hormonal contraceptives should be avoided solely due to obesity-related weight gain concerns* - The primary reason to avoid **combined hormonal contraceptives** in patients with a BMI ≥35 kg/m² is the significantly increased risk of **Venous Thromboembolism (VTE)**, not weight gain concerns. - For a patient with a BMI of 36 kg/m², these methods are categorized as **UKMEC 3** (risks generally outweigh benefits) due to cardiovascular safety profiles.
Question 117: A 50-year-old woman commenced on sequential combined HRT 4 months ago presents with withdrawal bleeding lasting 10 days, which is significantly heavier than her previous natural periods. Her cervical screening is up-to-date and normal. Abdominal and bimanual examination are unremarkable. What is the most appropriate initial investigation?
- A. Pelvic MRI scan
- B. Transvaginal ultrasound scan to assess endometrial thickness (Correct Answer)
- C. Endometrial biopsy
- D. Full blood count and serum ferritin
- E. Hysteroscopy and endometrial biopsy
Explanation: ***Transvaginal ultrasound scan to assess endometrial thickness***- A **transvaginal ultrasound (TVUS)** is the recommended first-line investigation for persistent or abnormal bleeding, even when on **sequential combined HRT**, to assess the **endometrium** and rule out pathology.- It provides a non-invasive way to measure **endometrial thickness**; a thickness of **<4 mm** in women on HRT (or postmenopausal bleeding) has a high negative predictive value for **endometrial cancer**.*Endometrial biopsy*- This is an invasive procedure typically reserved for cases where the **endometrial thickness** is significantly increased on **ultrasound** or if other suspicious features are identified.- It is not the primary initial step in evaluating abnormal bleeding in a woman on HRT unless **ultrasound** findings warrant it.*Full blood count and serum ferritin*- These tests assess for **iron deficiency anemia** resulting from heavy bleeding but do not identify the **underlying cause** of the abnormal uterine bleeding.- While important for managing the consequences of blood loss, they are not diagnostic investigations for **endometrial pathology** itself.*Pelvic MRI scan*- **MRI** is not a first-line diagnostic tool for evaluating **abnormal uterine bleeding** as it is expensive, less accessible, and provides less specific information for endometrial assessment than TVUS.- It is generally used for further characterization of **complex pelvic pathology** or staging known **malignancies** rather than initial screening for bleeding.*Hysteroscopy and endometrial biopsy*- This combination is considered the **gold standard** for diagnosing endometrial issues, allowing direct visualization and targeted biopsy, but is usually a **second-line** investigation after **TVUS**.- It is indicated if the **ultrasound** shows focal abnormalities (like **polyps**) or if bleeding persists despite normal initial scans and continued clinical concern.
Question 118: A 37-year-old woman with a BMI of 32 kg/m² presents requesting contraception. She has a history of migraine without aura occurring approximately twice monthly, well-controlled hypertension on ramipril 5 mg daily (blood pressure today 128/82 mmHg), and type 2 diabetes diagnosed 2 years ago managed with metformin (HbA1c 48 mmol/mol with no microvascular complications). She is a non-smoker. According to UK Medical Eligibility Criteria, which contraceptive method is classified as UKMEC 1 (no restriction) for this patient?
- A. Combined oral contraceptive pill
- B. Copper intrauterine device (Correct Answer)
- C. Progestogen-only injectable (depot medroxyprogesterone acetate)
- D. Vaginal contraceptive ring
- E. Combined transdermal patch
Explanation: ***Copper intrauterine device*** - The copper IUD is classified as **UKMEC 1** for this patient because it is a **non-hormonal** method, making it safe and unaffected by her medical history of hypertension, diabetes, or migraine. - It provides highly effective **long-acting reversible contraception (LARC)** without increasing the risk of cardiovascular events or interfering with glucose metabolism. *Combined oral contraceptive pill* - This method is categorized as **UKMEC 3** (risks outweigh benefits) due to the patient's **controlled hypertension** and **multiple cardiovascular risk factors**, including diabetes and obesity. - Estrogen-containing methods increase the risk of **venous thromboembolism (VTE)** and arterial disease, making them unsuitable for patients with such a risk profile. *Progestogen-only injectable (depot medroxyprogesterone acetate)* - Classified as **UKMEC 3** for patients with multiple risk factors for **cardiovascular disease** and those with a **BMI ≥30 kg/m²** due to potential metabolic effects. - There are additional concerns regarding its effect on **lipid metabolism** and glucose tolerance in patients already at higher metabolic risk. *Vaginal contraceptive ring* - Like the combined pill, this is a **combined hormonal contraceptive** and is classified as **UKMEC 3** because of her **hypertension** and significant metabolic risk factors (diabetes, obesity). - The **estrogen component** carries the same systemic **cardiovascular contraindications** as other combined hormonal methods, regardless of the route of administration. *Combined transdermal patch* - This method is also classified as **UKMEC 3** because it is a **combined hormonal contraceptive** containing estrogen, which is restricted in individuals with **hypertension** and multiple metabolic risk factors. - The patient's **BMI of 32 kg/m²** and **Type 2 Diabetes** further increase the absolute risk for thrombotic events when using estrogen-containing contraception.
Question 119: What is the minimum duration that women over the age of 50 years should continue using contraception after their last menstrual period to prevent pregnancy?
- A. 6 months
- B. 1 year (Correct Answer)
- C. 2 years
- D. 5 years
- E. Until FSH levels are consistently elevated above 30 IU/L
Explanation: ***1 year*** - According to **FSRH guidelines**, women **over the age of 50** are advised to continue contraception for **12 months** (1 year) after their last menstrual period (LMP). - This duration is sufficient because **fertility significantly declines** after age 50, making spontaneous ovulation and pregnancy highly unlikely after one year of amenorrhea. *6 months* - Six months is an **insufficient duration** to confirm the permanent cessation of ovarian function in women over 50. - Using this shorter timeframe increases the risk of **unintended pregnancy** due to potential sporadic ovulation during the perimenopausal transition. *2 years* - Continuance for **2 years** after the LMP is the specific recommendation for women **under the age of 50**. - Younger women have a higher **residual follicular reserve**, necessitating a longer period of amenorrhea to confirm menopause compared to those over 50. *5 years* - There is **no clinical evidence** to support a recommendation for 5 years of contraception post-LMP regardless of age. - Most women over 50 reach **sterility** naturally long before this timeframe; contraception is generally stopped by **age 55** regardless of menstrual history. *Until FSH levels are consistently elevated above 30 IU/L* - **FSH levels** are unreliable for determining when to stop contraception because they involve **significant fluctuations** during the perimenopausal period. - Clinical guidelines prioritize the **duration of amenorrhea** or the attainment of **age 55** over biochemical markers to guide contraceptive cessation.
Question 120: A 52-year-old woman who underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy 8 weeks ago for endometriosis presents with severe vasomotor symptoms affecting her quality of life and work performance. She has no personal or family history of venous thromboembolism or breast cancer. What is the most appropriate initial hormone replacement therapy regimen?
- A. Continuous combined HRT with estradiol 2 mg and norethisterone 1 mg
- B. Estradiol 2 mg oral tablet daily (Correct Answer)
- C. Sequential combined HRT with estradiol and dydrogesterone
- D. Transdermal estradiol 50 mcg patch twice weekly with micronised progesterone 200 mg daily
- E. Tibolone 2.5 mg daily
Explanation: ***Estradiol 2 mg oral tablet daily*** - In a patient who has undergone a **total abdominal hysterectomy** (removal of the uterus), the primary concern of endometrial hyperplasia due to unopposed estrogen is eliminated. Therefore, **estrogen-only HRT** is the most appropriate regimen for managing severe vasomotor symptoms. - The patient's history of **endometriosis** does not typically contraindicate estrogen-only HRT post-hysterectomy and oophorectomy, as the risk of **malignant transformation** or recurrence from residual implants is generally very low and does not routinely warrant progestogen. *Continuous combined HRT with estradiol 2 mg and norethisterone 1 mg* - This regimen includes a **progestogen** (norethisterone), which is primarily indicated for women with an **intact uterus** to counteract the proliferative effect of estrogen on the endometrium and prevent hyperplasia or cancer. - Since the patient has undergone a **hysterectomy**, the uterus is absent, rendering the progestogen component unnecessary and potentially increasing risks like **breast cancer** without providing endometrial protection. *Sequential combined HRT with estradiol and dydrogesterone* - **Sequential combined HRT** is designed for perimenopausal or recently menopausal women with an **intact uterus** to induce regular, predictable withdrawal bleeding by adding progestogen cyclically. - This patient is post-hysterectomy and **surgically menopausal**, meaning there is no uterus to bleed from, and the sequential progestogen is therefore inappropriate and redundant. *Transdermal estradiol 50 mcg patch twice weekly with micronised progesterone 200 mg daily* - While **transdermal estradiol** is a suitable estrogen delivery method, the inclusion of **micronised progesterone** is unwarranted for a patient without a uterus. - Progesterone is added to protect the **endometrium**, which is absent here. It would only be considered in rare cases of extensive residual endometriosis, not as a standard initial choice. *Tibolone 2.5 mg daily* - **Tibolone** is a synthetic steroid with estrogenic, progestogenic, and weak androgenic properties used to alleviate menopausal symptoms and prevent osteoporosis. - While it can be used post-hysterectomy, **estrogen-only HRT** (like estradiol) is generally considered the **first-line** and simpler approach for managing severe vasomotor symptoms in women without a uterus.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free